See the original post:
Tauriga Sciences, Inc. Now Configured to Accept the Following Cryptocurrencies as Payment Options on Its E-Commerce Platform: Bitcoin (BTC), Etherium...
PHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced the closing of its initial public offering of 2,250,000 shares of common stock at a public price offering of $8.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Vallon, were $18.0 million. In addition, Vallon has granted the underwriters a 45-day option to purchase up to an additional 337,500 shares of Vallon’s common stock at the initial public offering price, less underwriting discounts and commissions.
Continued here:
Vallon Pharmaceuticals Announces Closing of Initial Public Offering
LAKE FOREST, Ill., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) today announced that it closed its previously announced registered direct of common stock at a purchase price of $0.98 per share for gross proceeds of approximately $34.3 million.
Go here to see the original:
Assertio Holdings, Inc. Announces Closing of Registered Direct Offering of $34.3 Million
LONDON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the closing of its previously announced underwritten public offering in the United States of 16,428,572 American Depositary Shares (“ADSs”) representing 16,428,572 ordinary shares, including the exercise in full by the underwriters of their option to purchase an additional 2,142,857 ADSs, at a public offering price of $7.00 per ADS. The gross proceeds to Autolus from the offering, before underwriting discounts and commissions and other offering expenses payable by Autolus, were approximately $115.0 million.
See more here:
Autolus Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional ADSs
AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 4,081,633 shares of its common stock, at a purchase price per share of $49.00, for gross proceeds of approximately $200.0 million.
See the article here:
Cassava Sciences Announces Closing of $200 Million Registered Direct Offering
See the article here:
FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced...
Nes Ziona, Israel, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced the closing of its previously announced offering of 2,296,107 ordinary shares, par value NIS 0.40 per share, of the Company at a price to the public of $20.00 per ordinary share, less underwriting discounts and commissions.
Originally posted here:
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx
Read more:
Prime Minister, Boris Johnson visits Newcastle-based QuantuMDx
HOUSTON, Feb. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in a public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The rest is here:
Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock
